SCA
CBIO

SAC Capital Advisors’s Crescent Biopharma CBIO Stock Holding History

SAC Capital Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-286
Closed -$468K – 409
2014
Q1 		$468K Buy
+286
New +$346K ﹤0.01% 1213

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

SAC Capital Advisors's CBIO Position: Q2 2014 in Review

SAC Capital Advisors sold out of Crescent Biopharma (CBIO) in Q2 2014, closing a stake of 286 shares — an estimated $468K sold.

SAC Capital Advisors first reported a position in CBIO in Q1 2014 and held it in 1 quarter. The position peaked at $468K in Q1 2014. 32 funds tracked by Wall St. Rank hold CBIO as of Q2 2014.

  • SAC Capital Advisors reported no remaining Crescent Biopharma position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 286 Crescent Biopharma shares in Q2 2014, an estimated $468K.
  • SAC Capital Advisors first reported a position in Crescent Biopharma in Q1 2014 and held it in 1 quarter.
  • SAC Capital Advisors's Crescent Biopharma position peaked at $468K in Q1 2014.
  • 32 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.